Richmond-based Axon beat at least two other agencies to secure the account (PRWeek, 23 April), which sees the agency handling PR, medical education and ‘clinical research consulting’ for the Danish allergy vaccine giant.
Axon managing partner Ralph Sutton described his agency’s remit as ‘strategic’, adding that details of the campaign were still being thrashed out.
The product is yet to have a brand name and is undergoing clinical trials. The agency’s contract, which is understood to be potentially worth an annual budget of around £200,000, sees the agency report to ALK staff, including international marketing manager Ulf Blom.
Axon’s programme will be global with a focus on Europe. Axon is a subsidiary of Canadian comms giant National Public Relations.